In Silico screening for agonists and blockers of the β2 adrenergic receptor: Implications of inactive and activated state structures
暂无分享,去创建一个
[1] Cheng Zhang,et al. Structure and Function of an Irreversible Agonist-β2 Adrenoceptor complex , 2010, Nature.
[2] M. Bouvier,et al. The evasive nature of drug efficacy: implications for drug discovery. , 2007, Trends in pharmacological sciences.
[3] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[4] Santiago Vilar,et al. In silico analysis of the binding of agonists and blockers to the β2-adrenergic receptor. , 2011, Journal of molecular graphics & modelling.
[5] L. Fabbri,et al. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents , 2010, Respiratory research.
[6] Raymond C Stevens,et al. Discovery of new GPCR biology: one receptor structure at a time. , 2009, Structure.
[7] Robert J. Lefkowitz,et al. G-protein-coupled Receptor Kinase Specificity for β-Arrestin Recruitment to the β2-Adrenergic Receptor Revealed by Fluorescence Resonance Energy Transfer* , 2006, Journal of Biological Chemistry.
[8] Claudio N. Cavasotto,et al. Ligand-Steered Modeling and Docking: A Benchmarking Study in Class A G-Protein-Coupled Receptors , 2010, J. Chem. Inf. Model..
[9] Kenneth A Jacobson,et al. Molecular architecture of G protein‐coupled receptors , 1996, Drug development research.
[10] Ruben Abagyan,et al. Identifying conformational changes of the β2 adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators , 2009, J. Comput. Aided Mol. Des..
[11] Charles L. Brooks,et al. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.
[12] S. Gygi,et al. Global phosphorylation analysis of β-arrestin–mediated signaling downstream of a seven transmembrane receptor (7TMR) , 2010, Proceedings of the National Academy of Sciences.
[13] Santiago Vilar,et al. Ligand and structure‐based models for the prediction of ligand‐receptor affinities and virtual screenings: Development and application to the β2‐adrenergic receptor , 2009, J. Comput. Chem..
[14] Yang Xiang,et al. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. , 2004, The Journal of biological chemistry.
[15] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[16] Jonathan S. Mason,et al. Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.
[17] Brian K. Kobilka,et al. Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin , 1986, Nature.
[18] Jeremy R. Greenwood,et al. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules , 2007, J. Comput. Aided Mol. Des..
[19] J L Benovic,et al. The multiple membrane spanning topography of the beta 2-adrenergic receptor. Localization of the sites of binding, glycosylation, and regulatory phosphorylation by limited proteolysis. , 1987, The Journal of biological chemistry.
[20] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[21] Robert J. Lefkowitz,et al. β-Arrestin-biased Agonism at the β2-Adrenergic Receptor* , 2008, Journal of Biological Chemistry.
[22] D. Rognan,et al. Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.
[23] David Calkins,et al. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution , 2010, J. Comput. Aided Mol. Des..
[24] S. Rasmussen,et al. The structure and function of G-protein-coupled receptors , 2009, Nature.
[25] Xavier Deupi,et al. Conformational complexity of G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.
[26] S. Green,et al. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. , 1993, The Journal of biological chemistry.
[27] Claudio N. Cavasotto and Narender Singh. Docking and High Throughput Docking: Successes and the Challenge of Protein Flexibility , 2008 .
[28] R. Lefkowitz,et al. New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. , 2006, Molecular cell.
[29] R. Abagyan,et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.
[30] Robert J. Lefkowitz,et al. G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.
[31] Stefano Costanzi,et al. Rhodopsin and the others: a historical perspective on structural studies of G protein-coupled receptors. , 2009, Current pharmaceutical design.
[32] Sudarshan Rajagopal,et al. Quantifying Ligand Bias at Seven-Transmembrane Receptors , 2011, Molecular Pharmacology.
[33] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[34] Stefano Costanzi,et al. On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.
[35] R. Stevens,et al. GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function , 2007, Science.
[36] R. Friesner,et al. Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.
[37] Claudio N. Cavasotto,et al. Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models. , 2011, Journal of molecular graphics & modelling.
[38] Ja Johnson,et al. Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions , 2011, Clinical pharmacology and therapeutics.
[39] R. Stevens,et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor , 2007, Science.
[40] Ruben Abagyan,et al. GPCR 3D homology models for ligand screening: Lessons learned from blind predictions of adenosine A2a receptor complex , 2010, Proteins.
[41] Stefano Costanzi,et al. Modeling G Protein-Coupled Receptors: a Concrete Possibility. , 2010, Chimica oggi.
[42] P. Marin,et al. GPCR interacting proteins (GIP). , 2004, Pharmacology & therapeutics.
[43] Xavier Deupi,et al. Coupling ligand structure to specific conformational switches in the β2-adrenoceptor , 2006, Nature chemical biology.
[44] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..